| Australian United Investment Company Limited (AUI) ORDINARY FULLY PAID |
Financials |
$1,395 |
Update - Notification of buy-back - AUI
|
5 May 2025 9:03AM |
$10.500 |
$11.270 |
risen by
7.33%
|
|
| Torque Metals Limited (TOR) ORDINARY FULLY PAID |
Materials |
$179 |
DHEM confirmed as priority exploration technique at Paris
|
5 May 2025 9:02AM |
$0.093 |
$0.300 |
risen by
222.58%
|
|
TOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Multiple DHEM conductors identified at the Paris Gold Project.
- Gold is associated with sulphide minerals like pyrrhotite, pyrite, and chalcopyrite.
- Surveys detected conductors extending beyond current Mineral Resource Estimate boundaries.
- Plates 1 and 2 align with high-grade gold intercepts beyond the existing resource.
- DHEM is proving to be a reliable method for tracking mineralised structures.
- Over 4km of potential mineralisation remains untested by EM methods.
- The Paris Gold Project covers a 57km strike length within a highly prospective greenstone belt.
- Current Mineral Resource Estimate stands at 250,000 ounces of gold at 3.1 g/t.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gold Road Resources Limited (GOR) ORDINARY FULLY PAID |
Materials |
- |
Scheme Implementation Deed entered into with Gold Fields
|
5 May 2025 9:00AM |
$2.970 |
$3.480 |
risen by
17.17%
|
|
GOR - Price-sensitive ASX Announcement
Full Release
Key Points
- Gold Road Resources entered into a Scheme Implementation Deed with Gruyere Holdings Pty Ltd.
- The acquisition involves 100 percent of Gold Road's issued share capital.
- Shareholders will receive A$2.52 fixed cash consideration per share.
- Variable cash consideration based on Northern Star Resources shares adds to the total value.
- Total scheme consideration equates to A$3.40 per share, valuing Gold Road at A$3.7 billion.
- The fixed cash consideration is a 59 percent premium over the share price on 21 March 2025.
- A fully franked special dividend of approximately A$0.35 per share is planned.
- Gold Fields stated the proposed consideration is the best and final price.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| RocketBoots Limited (ROC) ORDINARY FULLY PAID |
Information Technology |
$45 |
Proposed issue of securities - ROC
|
5 May 2025 8:59AM |
$0.085 |
$0.265 |
risen by
211.76%
|
|
| OD6 Metals Limited (OD6) ORDINARY FULLY PAID |
Materials |
$15 |
Gulf Creek Exploration Set to Recommence
|
5 May 2025 8:58AM |
$0.022 |
$0.074 |
risen by
236.36%
|
|
OD6 - Price-sensitive ASX Announcement
Full Release
Key Points
- OD6 Metals Limited is recommencing exploration at Gulf Creek Copper Project.
- The NSW Resources Regulator revoked a prior notice that halted activities.
- The company completed 6 of 9 planned drill holes before the notice.
- Assay results and geological interpretations are expected soon.
- OD6 aims to explore both brownfield and greenfield opportunities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Duxton Water Limited (D2O) ORDINARY FULLY PAID |
Utilities |
$238 |
Update - Notification of buy-back - D2O
|
5 May 2025 8:58AM |
$1.550 |
$1.530 |
fallen by
1.29%
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$504 |
Race Announces Key Senior Clinical Team Appointments
|
5 May 2025 8:57AM |
$1.210 |
$2.790 |
risen by
130.58%
|
|
| Group 6 Metals Limited (G6M) ORDINARY FULLY PAID |
Materials |
$6 |
Change in substantial holding - Ellis
|
5 May 2025 8:57AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Group 6 Metals Limited (G6M) ORDINARY FULLY PAID |
Materials |
$6 |
Change in substantial holding - Elphinstone
|
5 May 2025 8:56AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$458 |
Proposed issue of securities - RXL
|
5 May 2025 8:56AM |
$0.360 |
$0.480 |
risen by
33.33%
|
|
| Group 6 Metals Limited (G6M) ORDINARY FULLY PAID |
Materials |
$6 |
Change of Director's Interest Notice x3
|
5 May 2025 8:56AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$458 |
Institutional Placement to Accelerate Project Development
|
5 May 2025 8:56AM |
$0.360 |
$0.480 |
risen by
33.33%
|
|
RXL - Price-sensitive ASX Announcement
Full Release
Key Points
- Approximately A$40 million to be raised through institutional placement.
- Strong support from international and domestic investors.
- Funds will support early works at the Youanmi Gold Project.
- Cash position estimated at A$57.1 million post-placement.
- Key activities include underground development and camp construction.
- The placement issue price represents a discount to the last closing price.
- First tranche expected to settle by 12 May 2025.
- Second tranche subject to shareholder approval in June 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Group 6 Metals Limited (G6M) ORDINARY FULLY PAID |
Materials |
$6 |
Notification regarding unquoted securities - G6M
|
5 May 2025 8:56AM |
$0.025 |
$0.025 |
fallen by
0%
|
|
| Apiam Animal Health Limited (AHX) ORDINARY FULLY PAID |
Health Care |
$161 |
Investor Update
|
5 May 2025 8:56AM |
$0.430 |
$0.870 |
risen by
102.33%
|
|
AHX - Price-sensitive ASX Announcement
Full Release
Key Points
- Apiam Animal Health reported a revenue of 156.6 million AUD for FY25 YTD.
- Gross profit remained stable at 104.1 million AUD, showing a slight decline from the previous year.
- EBITDA decreased by 1.5% to 15.4 million AUD compared to FY24.
- NPATA fell by 9.4% to 5.4 million AUD year-over-year.
- Equine markets have shown weaker conditions, impacting the Clinical Vet Services segment.
- Intensive Animal Veterinary services are expected to contribute significantly to FY25 results.
- The company divested two underperforming clinics, removing a negative EBIT impact of 1 million AUD annually.
- The rollout of CoVet, an AI-driven clinical tool, aims to enhance operational efficiencies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Gale Pacific Limited (GAP) ORDINARY FULLY PAID |
Consumer Discretionary |
$27 |
Trading Update
|
5 May 2025 8:54AM |
$0.100 |
$0.095 |
fallen by
5%
|
|
GAP - Price-sensitive ASX Announcement
Full Release
Key Points
- Q4 trading in the US is expected to be impacted by reduced consumer demand due to new tariffs.
- Existing US inventory is unaffected by tariffs introduced after 2 April 2025.
- US retail partners are cautious about replenishing inventory.
- Performance in Australia, New Zealand, and Developing Markets remains on track.
- The strategy to diversify manufacturing outside of China is progressing well.
- Revised full year EBITDA guidance is between $10 million and $12 million.
- GALE CEO noted anticipated declining consumer confidence and cautious inventory approaches.
- Ongoing tariff-related price negotiations with US customers.
- Further details on market conditions will be shared in the FY25 full year results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Alterity Therapeutics Limited (ATH) ORDINARY FULLY PAID |
Health Care |
$92 |
Alterity Granted U.S. FDA Fast Track Designation for ATH434
|
5 May 2025 8:53AM |
$0.009 |
$0.009 |
fallen by
5.56%
|
|
ATH - Price-sensitive ASX Announcement
Full Release
Key Points
- Alterity Therapeutics granted U.S. FDA Fast Track designation for ATH434.
- ATH434 aims to treat Multiple System Atrophy (MSA), a disease with no approved therapy.
- Fast Track designation allows for accelerated development and review processes.
- ATH434 demonstrated robust clinical efficacy in recent Phase 2 clinical trials.
- The drug has potential as a disease-modifying therapy for neurodegenerative diseases.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$508 |
Notification of cessation of securities - INR
|
5 May 2025 8:53AM |
$0.135 |
$0.190 |
risen by
40.74%
|
|
| Quickstep Holdings Limited (QHL) ORDINARY FULLY PAID |
Industrials |
- |
Implementation of Scheme of Arrangement
|
5 May 2025 8:52AM |
$0.575 |
$0.575 |
fallen by
0%
|
|
| City Chic Collective Limited (CCX) ORDINARY FULLY PAID |
Consumer Discretionary |
$44 |
US Tariff and Trading Update
|
5 May 2025 8:52AM |
$0.084 |
$0.115 |
risen by
36.90%
|
|
CCX - Price-sensitive ASX Announcement
Full Release
Key Points
- Increased global tariff rates announced by the US government, significantly affecting imports from China.
- Approximately 20% of City Chic's revenue is generated in the USA, with over 90% of products sourced from China.
- Proactive inventory management has mitigated some tariff effects, sustaining operations into Q2 FY26.
- USA sales expectations for FY26 have been reduced due to potential impacts on consumer demand.
- The management is closely monitoring peer retailers and market conditions, with cost reductions implemented.
- Despite a strong performance in ANZ, the USA market is down by 13% on prior comparable period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chrysos Corporation Limited (C79) ORDINARY FULLY PAID |
Industrials |
$883 |
May 2025 Trading Update
|
5 May 2025 8:52AM |
$4.140 |
$7.580 |
risen by
83.09%
|
|
C79 - Price-sensitive ASX Announcement
Full Release
Key Points
- Chrysos reported Q3 FY25 unaudited revenue of $16.2 million.
- Revenue increased 5% quarter-on-quarter and 25% year-on-year.
- Sample volumes processed totaled 1.7 million, with a 57% growth year-on-year.
- The company is deploying five PhotonAssayTM units.
- Chrysos has contracted a total of 58 PhotonAssayTM units.
- FY25 revenue guidance remains between $60 million to $70 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| iShares Yield Plus ETF (IYLD) |
Financials |
$86 |
ESTIMATED DISTRIBUTION ANNOUNCEMENT
|
5 May 2025 8:50AM |
$100.570 |
$100.470 |
fallen by
0.10%
|
|
| Ishares Enhanced Cash ETF (ISEC) |
Financials |
$489 |
ESTIMATED DISTRIBUTION ANNOUNCEMENT
|
5 May 2025 8:50AM |
$100.880 |
$100.730 |
fallen by
0.15%
|
|
| iShares Core Cash ETF (BILL) |
Financials |
$1,084 |
ESTIMATED DISTRIBUTION ANNOUNCEMENT
|
5 May 2025 8:50AM |
$100.770 |
$100.660 |
fallen by
0.11%
|
|
| ioneer Ltd (INR) ORDINARY FULLY PAID |
Materials |
$508 |
Notification regarding unquoted securities - INR
|
5 May 2025 8:49AM |
$0.135 |
$0.190 |
risen by
40.74%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$31,390 |
Notification of cessation of securities - BXB
|
5 May 2025 8:49AM |
$20.800 |
$23.110 |
risen by
11.11%
|
|